Accueil038290 • KOSDAQ
add
Macrogen Inc
Dernière clôture
16 150,00 ₩
Variation sur la journée
16 210,00 ₩ - 16 650,00 ₩
Plage sur l'année
14 920,00 ₩ - 26 700,00 ₩
Capitalisation boursière
177,01 Md KRW
Volume moyen
62,86 k
Ratio cours/bénéfices
-
Rendement (dividendes)
1,82 %
Place boursière principale
KOSDAQ
Actualités des marchés
Données financières
Compte de résultat
Chiffre d'affaires
Résultat net
| (KRW) | sept. 2024info | Variation Y/Y |
|---|---|---|
Chiffre d'affaires | 33,00 Md | 2,20 % |
Charges d'exploitation | 13,80 Md | 4,68 % |
Résultat net | -3,18 Md | -60,92 % |
Marge bénéficiaire nette | -9,64 | -57,52 % |
Bénéfice par action | — | — |
EBITDA | 2,21 Md | 47,21 % |
Taux d'imposition effectif | 1,20 % | — |
Bilan
Total des actifs
Total du passif
| (KRW) | sept. 2024info | Variation Y/Y |
|---|---|---|
Trésorerie/Invest. court terme | 24,60 Md | 8,61 % |
Total des actifs | 274,19 Md | 3,79 % |
Total du passif | 124,82 Md | 40,99 % |
Total des capitaux propres | 149,37 Md | — |
Actions en circulation | 9,97 M | — |
Ratio cours/valeur comptable | 1,09 | — |
Rentabilité des actifs | -0,54 % | — |
Retour sur capitaux | -0,70 % | — |
Flux de trésorerie
Variation nette en trésorerie
| (KRW) | sept. 2024info | Variation Y/Y |
|---|---|---|
Résultat net | -3,18 Md | -60,92 % |
Trésorerie (opérations) | -2,08 Md | 50,99 % |
Trésorerie (invest.) | -9,57 Md | -22,48 % |
Trésorerie (financement) | 6,73 Md | 594,06 % |
Variation nette en trésorerie | -4,51 Md | 58,99 % |
Flux de trésorerie dispo. | -10,07 Md | 35,34 % |
À propos
Macrogen, Inc. is a South Korean public biotechnology company. The company's headquarters are located in Seoul. The company was founded in 1997 by Jeong-sun Seo, a professor at Seoul National University. It was venture capital-backed until its initial public offering and subsequent listing on the KOSDAQ market in 2000, making it the first Korean biotechnology firm to raise funds through an IPO. The company announced plans in 2010 to map the "Korean genome" based on the notion that United States-backed genome mapping efforts up to that time were representative of the "Caucasian genome" rather than the "Human genome" as claimed. By 2015, the company was described by one news outlet as "a global leader in personalized genomic medicine". Wikipedia
Date de fondation
5 juin 1997
Site Web
Employés
519
